Yield10 Bioscience (OTCPK:YTEN) - Cours de l'action, nouvelles et analyse

YTEN Aperçu des actions

Yield10 Bioscience, Inc. est une société de biosciences agricoles qui se concentre sur la commercialisation de produits utilisant les graines oléagineuses de Camelina aux États-Unis. Plus de détails

YTEN analyse fondamentale
Score flocon de neige
Évaluation	2/6
Croissance future	0/6
Performances passées	0/6
Santé financière	2/6
Dividendes	0/6

Analyse des risques

Capitaux propres négatifs

N'a pas de capitalisation boursière significative ( $216K )

Réalise moins d'un million de dollars de revenus ( $750K )

Les revenus ont diminué de 5.5% par an au cours des 5 dernières années

+ 2 plus de risques

Yield10 Bioscience, Inc. Concurrents

Endonovo Therapeutics

OTCPK:ENDV

US$317.5k

Capstone Holding

OTCPK:CAPS

US$504.4k

Bellicum Pharmaceuticals

OTCPK:BLCM

US$879.5k

Bellerophon Therapeutics

OTCPK:BLPH

US$672.8k

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Yield10 Bioscience
Historique des cours de bourse
Prix actuel de l'action	US$0.42
Plus haut sur 52 semaines	US$17.26
Plus bas sur 52 semaines	US$0.31
Bêta	1.43
1Variation sur 1 mois	-51.77%
Variation sur 3 mois	-61.58%
Variation sur 1 an	-92.96%
3Variation sur 3 ans	-99.64%
Variation sur 5 ans	-99.71%
Évolution depuis l'introduction en bourse	-100.00%

Nouvelles et mises à jour récentes

Recent updates

Yield10 Bioscience GAAP EPS of $0.70 beats by $1.39, revenue of $0.1M misses by $0.06M

Aug 10

Is Yield10 Bioscience (NASDAQ:YTEN) In A Good Position To Invest In Growth?

Nov 12

Yield10 Bioscience (NASDAQ:YTEN) Is In A Good Position To Deliver On Growth Plans

Jul 19

Yield10 Bioscience, Inc.'s (NASDAQ:YTEN) CEO Will Probably Find It Hard To See A Huge Raise This Year

May 18

Here's Why We're Watching Yield10 Bioscience's (NASDAQ:YTEN) Cash Burn Situation

Apr 14

Rendement pour les actionnaires

	YTEN	US Biotechs	US Marché
7D	-36.0%	4.0%	2.0%
1Y	-93.0%	18.0%	32.4%

Rendement vs Industrie: YTEN a sous-performé le secteur US Biotechs qui a rapporté 18 % au cours de l'année écoulée.

Rendement vs marché: YTEN a sous-performé le marché US qui a rapporté 32.4 % au cours de l'année écoulée.

Volatilité des prix

Is YTEN's price volatile compared to industry and market?
YTEN volatility
YTEN Average Weekly Movement	39.7%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

Cours de l'action stable: Le cours de l'action de YTEN a été volatil au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de YTEN est passée de 32% à 40% au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
1992	29	Olly Peoples	www.yield10bio.com

Yield10 Bioscience, Inc. est une société de biosciences agricoles qui se concentre sur la commercialisation de produits utilisant les graines oléagineuses de caméline aux États-Unis. Ses produits comprennent l'huile de caméline pour la production de niveaux élevés d'acides gras oméga-3, l'acide eicosapentanoïque (EPA) et l'acide docosahexanoïque (DHA), et pour l'utilisation comme huile de charge à faible intensité de carbone pour les biocarburants, y compris le biodiesel, le diesel renouvelable (RD), et le carburant d'aviation durable (SAF). La société était auparavant connue sous le nom de Metabolix, Inc. et a changé de nom pour devenir Yield10 Bioscience, Inc. en janvier 2017.

Yield10 Bioscience, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Yield10 Bioscience se comparent-ils à sa capitalisation boursière ?
YTEN statistiques fondamentales
Capitalisation boursière	US$216.46k
Bénéfices(TTM)	-US$12.70m
Recettes(TTM)	US$750.00k

0.4x

Ratio P/S

0.0x

Ratio P/E

Le site YTEN est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
YTEN compte de résultat (TTM)
Recettes	US$750.00k
Coût des recettes	US$7.21m
Marge brute	-US$6.46m
Autres dépenses	US$6.25m
Les revenus	-US$12.70m

Derniers bénéfices déclarés

Jun 30, 2024

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-18.34
Marge brute	-860.93%
Marge bénéficiaire nette	-1,693.60%
Ratio dettes/capitaux propres	-16.0%

Quelles ont été les performances à long terme de YTEN?

Voir les performances historiques et les comparaisons

YTEN Aperçu des actions

Analyse des risques

Yield10 Bioscience, Inc. Concurrents

OTCPK:ENDV

US$317.5k

OTCPK:CAPS

US$504.4k

OTCPK:BLCM

US$879.5k

OTCPK:BLPH

US$672.8k

Historique des prix et performances

Nouvelles et mises à jour récentes

Yield10 Bioscience, Inc. announced that it has received $3 million in funding

Nuseed Nutritional US Inc. entered into an asset purchase agreement to acquire Substantially all assets of Yield10 Bioscience, Inc./Yield10 Oilseeds, Inc. from Yield10 Bioscience, Inc. (OTCPK:YTEN) and Yield10 Oilseeds, Inc. for $5 million.

Yield10 Bioscience, Inc.(OTCPK:YTEN) dropped from NASDAQ Composite Index

Yield10 Bioscience Announces Delisting from Nasdaq

Yield10 Bioscience Announces 1-for-24 Reverse Stock Split to Increase the Market Price Per Share of the its Common Stock to Maintain the Listing of its Common Stock on The Nasdaq Capital Market

Yield10 Bioscience, Inc., Annual General Meeting, Jun 07, 2024

Recent updates

Yield10 Bioscience, Inc. announced that it has received $3 million in funding

Nuseed Nutritional US Inc. entered into an asset purchase agreement to acquire Substantially all assets of Yield10 Bioscience, Inc./Yield10 Oilseeds, Inc. from Yield10 Bioscience, Inc. (OTCPK:YTEN) and Yield10 Oilseeds, Inc. for $5 million.

Yield10 Bioscience, Inc.(OTCPK:YTEN) dropped from NASDAQ Composite Index

Yield10 Bioscience Announces Delisting from Nasdaq

Yield10 Bioscience Announces 1-for-24 Reverse Stock Split to Increase the Market Price Per Share of the its Common Stock to Maintain the Listing of its Common Stock on The Nasdaq Capital Market

Yield10 Bioscience, Inc., Annual General Meeting, Jun 07, 2024

Yield10 Bioscience Receives Written Notice from The Nasdaq Stock Market LLC Regarding Not Eligible for Second 180 Day Compliance Period for the Minimum Bid Price Rule Deficiency

Yield10 Bioscience, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Yield10 Bioscience, Inc. Announces the Plant Biosafety Office of the Canadian Food Inspection Agency Clear Genome-edited E3902 Camelina for Planting in Canada

Nasdaq Hearings Panel Grants Yield10 Bioscience, Inc. an Additional Extension to Remain Listed on the Nasdaq Capital Market Until May 13, 2024

Yield10 Bioscience, Inc. Provides an Update on Its Omega-3 Camelina Program

Yield10 Bioscience, Inc. Files Request for Regulatory Status Review with USDA-APHIS for Camelina Designed to Produce the EPA and DHA Components of Omega-3 Oil

Yield10 Bioscience Receives Non-Compliance Notice From Nasdaq

Yield10 Bioscience, Inc. Contemplates Bankruptcy.

Yield10 Bioscience, Inc. Contemplates Bankruptcy.

Yield10 Bioscience, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Yield10 Bioscience, Inc. Provides Update on Recent Advancements in the Development of Elite Herbicide Tolerant Camelina

Yield10 Bioscience, Inc. Receives Non-Compliance Notice from Nasdaq

Yield10 Bioscience, Inc. has completed a Composite Units Offering in the amount of $3.7375 million.

Price target decreased by 33% to US$9.83

Second quarter 2023 earnings released: US$0.64 loss per share (vs US$0.70 loss in 2Q 2022)

New major risk - Shareholder dilution

Yield10 Bioscience, Inc. to Report Q2, 2023 Results on Aug 14, 2023

New major risk - Market cap size

Yield10 Bioscience, Inc. Announces Positive Results in the First Field Test of Stacked Herbicide Tolerance Traits in Camelina

New minor risk - Share price stability

Yield10 Bioscience Files Request for Regulatory Status Review Under Usda-Aphis’S Secure Rule Covering Elite Camelina Designed to Produce the EPA Component of Omega-3 Oil

Yield10 Bioscience Receives A Deficiency Letter from Nasdaq Regarding Minimum Stockholders' Equity Requirement for Continued Listing on the Nasdaq Capital Market

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Insider recently bought US$1m worth of stock

Yield10 Bioscience, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$14.67

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$14.67

Yield10 Bioscience, Inc. Begins Winter 2022/2023 Field Test and Seed Production Program

Yield10 Bioscience, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Yield10 Bioscience, Inc. Appoints Willie Loh to Its Board of Directors

Yield10 Bioscience, Inc. Appoints Willie Loh to Its Board of Directors

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Yield10 Bioscience GAAP EPS of $0.70 beats by $1.39, revenue of $0.1M misses by $0.06M

Yield10 Bioscience, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Yield10 Bioscience, Inc. to Report Q1, 2022 Results on May 11, 2022

Price target decreased to US$15.33

Yield10 Bioscience, Inc., Annual General Meeting, May 25, 2022

Yield10 Bioscience, Inc., Annual General Meeting, May 25, 2022

Price target decreased to US$17.00

Yield10 Bioscience Announces Recent Advances in the Development of Camelina as A Production Platform for PHA Bioplastic

Yield10 Bioscience, Inc. Announces an Update on the Camelina Line E3902 Development Program

Yield10 Bioscience, Inc. to Report Q4, 2021 Results on Mar 09, 2022

Is Yield10 Bioscience (NASDAQ:YTEN) In A Good Position To Invest In Growth?

Third quarter 2021 earnings released: US$0.49 loss per share (vs US$0.87 loss in 3Q 2020)

Consensus revenue estimates fall to US$890.0k

Price target decreased to US$21.50

Second quarter 2021 earnings released: US$0.64 loss per share (vs US$0.92 loss in 2Q 2020)

Yield10 Bioscience (NASDAQ:YTEN) Is In A Good Position To Deliver On Growth Plans

Yield10 Bioscience, Inc. Begins 2021 Field Test and Seed Scale Up Program